DAR File No. 39780
This rule was published in the October 15, 2015, issue (Vol. 2015, No. 20) of the Utah State Bulletin.
Commerce, Occupational and Professional Licensing
Pharmacy Practice Act Rule
Notice of Proposed Rule
DAR File No.: 39780
Filed: 09/29/2015 03:20:08 PM
Purpose of the rule or reason for the change:
During the 2015 Legislative Session, S.B. 158 passed and amended Title 58, Chapter 17b, the Pharmacy Practice Act. The statutory amendment granted the division rulemaking authority in order to establish guidelines for medical practitioners to dispense drugs to patients in a hospital emergency department. The division and State Board of Pharmacy have reviewed this rule and have determined the purpose of this rule filing is to remove a rule section that will become obsolete because of the proposed amendments in this rule filing and to codify the guidelines under which medical practitioners may dispense drugs to patients in a hospital emergency department and amend the rule governing when a temporary pharmacist license may be issued. This filing also updates the edition of the United States Pharmacopeia-National Formulary (USP-NF) books which are incorporated by reference in the rule.
Summary of the rule or change:
Subsection R156-17b-102(57) is amended to update to the 2015 edition date of the USP-NF books which are incorporated by reference. In Section R156-17b-304, the amendments make the requirements for a temporary pharmacist license less restrictive by removing the requirement that an applicant be enrolled in the second year of a pharmacy graduate residency. It also adds that a temporary pharmacist license may be issued to an applicant in a fellowship program. Section R156-17b-610.5, is a new section that establishes the guidelines under which medical practitioners may dispense drugs to patients in a hospital emergency department. Section R156-17b-614e is being deleted because it will become obsolete after the implementation of the guidelines in new Section R156-17b-610.5.
State statutory or constitutional authorization for this rule:
- Subsection 58-17b-601(1)
- Section 58-17b-101
- Subsection 58-1-106(1)(a)
- Section 58-37-1
- Subsection 58-1-202(1)(a)
This rule or change incorporates by reference the following material:
- Updates United States Pharmacopeia-National Formulary (USP 38-NF33) through Supplement 2, published by United States Pharmacopeia, 2015
Anticipated cost or savings to:
the state budget:
The division will incur minimal costs of approximately $75 to print and distribute the rule once the proposed amendments are made effective. Any costs incurred will be absorbed in the division's current budget.
The proposed amendments apply only to licensees provided in Title 58, Chapter 17b. As a result, the proposed amendments do not apply to local governments.
The proposed amendments apply only to licensees provided in Title 58, Chapter 17b. No fiscal impact to small businesses is anticipated with respect to the proposed amendments involving hospital emergency department dispensing guidelines. The new proposed language adds clarification to practices that already exist in the industry. However, small businesses who operate as a pharmacy would be required to maintain the updated 2015 edition of the USP-NF reference books. An annual subscription renewal for the USP-NF books is approximately $900. There are approximately 2640 licensed pharmacies, which may or may not qualify as a small business, which would have an aggregate cost of $2,376,000 for all to maintain an annual subscription renewal.
persons other than small businesses, businesses, or local governmental entities:
The proposed amendments apply only to licensees provided in Title 58, Chapter 17b. No fiscal impact to other persons is anticipated with respect to the proposed amendments involving hospital emergency department dispensing guidelines. However, other persons who operate a pharmacy would be required to maintain the updated 2015 edition of the USP-NF reference books. An annual subscription renewal for the USP-NF books is approximately $900.
Compliance costs for affected persons:
The proposed amendments apply only to licensees provided in Title 58, Chapter 17b. No fiscal impact to affected persons is anticipated with respect to the proposed amendments involving hospital emergency department dispensing guidelines. However, affected persons who operate a pharmacy would be required to maintain the updated 2015 edition of the USP-NF reference books. An annual subscription renewal for the USP-NF books is approximately $900.
Comments by the department head on the fiscal impact the rule may have on businesses:
As stated in the rule analysis, this filing clarifies existing provisions, as required by Legislative action (S.B. 158 2015). No fiscal impact to businesses is anticipated.
Francine A. Giani, Executive Director
The full text of this rule may be inspected, during regular business hours, at the Division of Administrative Rules, or at:Commerce
Occupational and Professional Licensing
HEBER M WELLS BLDG
160 E 300 S
SALT LAKE CITY, UT 84111-2316
Direct questions regarding this rule to:
- Dane Ishihara at the above address, by phone at 801-530-7632, by FAX at 801-530-6511, or by Internet E-mail at email@example.com
Interested persons may present their views on this rule by submitting written comments to the address above no later than 5:00 p.m. on:
Interested persons may attend a public hearing regarding this rule:
- 10/27/2015 08:30 AM, Heber Wells Bldg, 160 E 300 S, Conference Room 474 (fourth floor), Salt Lake City, UT
This rule may become effective on:
Mark Steinagel, Director
R156. Commerce, Occupational and Professional Licensing.
R156-17b. Pharmacy Practice Act Rule.
In addition to the definitions in Title 58, Chapters 1 and 17b, as used in Title 58, Chapters 1 and 17b or this rule:
(1) "Accredited by ASHP" means a program that:
(a) was accredited by the ASHP on the day the applicant for licensure completed the program; or
(b) was in ASHP candidate status on the day the applicant for licensure completed the program.
(2) "ACPE" means the American Council on Pharmaceutical Education or Accreditation Council for Pharmacy Education.
(3) "Analytical laboratory":
(a) means a facility in possession of prescription drugs for the purpose of analysis; and
(b) does not include a laboratory possessing prescription drugs used as standards and controls in performing drug monitoring or drug screening analysis if the prescription drugs are pre-diluted in a human or animal body fluid, human or animal body fluid components, organic solvents, or inorganic buffers at a concentration not exceeding one milligram per milliliter when labeled or otherwise designated as being for in-vitro diagnostic use.
(4) "ASHP" means the American Society of Health System Pharmacists.
(5) "Authorized distributor of record" means a pharmaceutical wholesaler with whom a manufacturer has established an ongoing relationship to distribute the manufacturer's prescription drugs. An ongoing relationship is deemed to exist between such pharmaceutical wholesaler and a manufacturer, as defined in Section 1504 of the Internal Revenue Code, when the pharmaceutical wholesaler has a written agreement currently in effect with the manufacturer evidencing such ongoing relationship, and the pharmaceutical wholesaler is listed on the manufacturer's current list of authorized distributors of record.
(6) "Authorized personnel" means any person who is a part of the pharmacy staff who participates in the operational processes of the pharmacy and contributes to the natural flow of pharmaceutical care.
(7) "Centralized Prescription Filling" means the filling by a pharmacy of a request from another pharmacy to fill or refill a prescription drug order.
(8) "Centralized Prescription Processing" means the processing by a pharmacy of a request from another pharmacy to fill or refill a prescription drug order or to perform processing functions such as dispensing, drug utilization review (DUR), claims adjudication, refill authorizations, and therapeutic interventions.
(9) "Chain pharmacy warehouse" means a physical location for prescription drugs that acts as a central warehouse and performs intracompany sales or transfers of the prescription drugs to a group of chain pharmacies that have the same common ownership and control.
(10) "Co-licensed partner or product" means an instance where two or more parties have the right to engage in the manufacturing and/or marketing of a prescription drug, consistent with FDA's implementation of the Prescription Drug Marketing Act.
(11) "Cooperative pharmacy warehouse" means a physical location for drugs that acts as a central warehouse and is owned, operated or affiliated with a group purchasing organization (GPO) or pharmacy buying cooperative and distributes those drugs exclusively to its members.
(12) "Counterfeit prescription drug" has the meaning given that term in 21 USC 321(g)(2), including any amendments thereto.
(13) "Counterfeiting" means engaging in activities that create a counterfeit prescription drug.
(14) "Dispense", as defined in Subsection 58-17b-102(22), does not include transferring medications for a patient from a legally dispensed prescription for that particular patient into a daily or weekly drug container to facilitate the patient taking the correct medication.
(15) "Device" means an instrument, apparatus, implement, machine, contrivance, implant, or other similar or related article, including any component part or accessory, which is required under Federal law to bear the label, "Caution: Federal or State law requires dispensing by or on the order of a physician."
(16) "DMP" means a dispensing medical practitioner licensed under Section 58-17b, Part 8.
(17) "DMP designee" means an individual, acting under the direction of a DMP, who:
(a)(i) holds an active health care professional license under one of the following chapters:
(A) Chapter 67, Utah Medical Practice Act;
(B) Chapter 68, Utah Osteopathic Medical Practice Act;
(C) Chapter 70a, Physician Assistant Act;
(D) Chapter 31b, Nurse Practice Act;
(E) Chapter 16a, Utah Optometry Practice Act;
(F) Chapter 44a, Nurse Midwife Practice Act; or
(G) Chapter 17b, Pharmacy Practice Act; or
(ii) is a medical assistant as defined in Subsection 58-67-102 (9);
(b) meets requirements established in Subsection 58-17b-803 (4)(c); and
(c) can document successful completion of a formal or on-the-job dispensing training program that meets standards established in Section R156-17b-622.
(18) "DMPIC" means a dispensing medical practitioner licensed under Section 58-17b, Part 8 who is designated by a dispensing medical practitioner clinic pharmacy to be responsible for activities of the pharmacy.
(19) "Drop shipment" means the sale of a prescription drug to a pharmaceutical wholesaler by the manufacturer of the drug; by the manufacturer's co-licensed product partner, third party logistics provider, or exclusive distributor; or by an authorized distributor of record that purchased the product directly from the manufacturer or from one of these entities; whereby:
(a) the pharmaceutical wholesale distributor takes title to but not physical possession of such prescription drug;
(b) the pharmaceutical wholesale distributor invoices the pharmacy, pharmacy warehouse, or other person authorized by law to dispense to administer such drug; and
(c) the pharmacy, pharmacy warehouse, or other person authorized by law to dispense or administer such drug receives delivery of the prescription drug directly from the manufacturer; from the co-licensed product partner, third party logistics provider, or exclusive distributor; or from an authorized distributor of record that purchases the product directly from the manufacturer or from one of these entities.
(20) "Drug therapy management" means the review of a drug therapy regimen of a patient by one or more pharmacists for the purpose of evaluating and rendering advice to one or more practitioners regarding adjustment of the regimen.
(21) "Drugs", as used in this rule, means drugs or devices.
(22) "Durable medical equipment" or "DME" means equipment that:
(a) can withstand repeated use;
(b) is primarily and customarily used to serve a medical purpose;
(c) generally is not useful to a person in the absence of an illness or injury;
(d) is suitable for use in a health care facility or in the home; and
(e) may include devices and medical supplies.
(23) "Entities under common administrative control" means an entity holds the power, actual as well as legal to influence the management, direction, or functioning of a business or organization.
(24) "Entities under common ownership" means entity assets are held indivisibly rather than in the names of individual members.
(25) "ExCPT", as used in this rule, means the Exam for the Certification of Pharmacy Technicians.
(26) "FDA" means the United States Food and Drug Administration and any successor agency.
(27) "High-risk, medium-risk, and low-risk drugs" refers to the risk to a patient's health from compounding sterile preparations, as referred to in USP-NF Chapter 797, for details of determining risk level.
(28) "Hospice facility pharmacy" means a pharmacy that supplies drugs to patients in a licensed healthcare facility for terminal patients.
(29) "Hospital clinic pharmacy" means a pharmacy that is located in an outpatient treatment area where a pharmacist or pharmacy intern is compounding, admixing, or dispensing prescription drugs, and where:
(a) prescription drugs or devices are under the control of the pharmacist, or the facility for administration to patients of that facility;
(b) prescription drugs or devices are dispensed by the pharmacist or pharmacy intern; or
(c) prescription drugs are administered in accordance with the order of a practitioner by an employee or agent of the facility.
(30) "Legend drug" or "prescription drug" means any drug or device that has been determined to be unsafe for self-medication or any drug or device that bears or is required to bear the legend:
(a) "Caution: federal law prohibits dispensing without prescription";
(b) "Caution: federal law restricts this drug to use by or on the order of a licensed veterinarian"; or
(c) "Rx only".
(31) "Maintenance medications" means medications the patient takes on an ongoing basis.
(32) "Manufacturer's exclusive distributor" means an entity that contracts with a manufacturer to provide or coordinate warehousing, distribution, or other services on behalf of a manufacturer and who takes title to that manufacturer's prescription drug, but who does not have general responsibility to direct the drug's sale or disposition. Such manufacturer's exclusive distributor shall be licensed as a pharmaceutical wholesaler under this chapter and be an "authorized distributor of record" to be considered part of the "normal distribution channel".
(33) "Medical supplies" means items for medical use that are suitable for use in a health care facility or in the home and that are disposable or semi-disposable and are non-reusable.
(34) "MPJE" means the Multistate Jurisprudence Examination.
(35) "NABP" means the National Association of Boards of Pharmacy.
(36) "NAPLEX" means North American Pharmacy Licensing Examination.
(37) "Normal distribution channel" means a chain of custody for a prescription drug that goes directly, by drop shipment as defined in Subsection (19), or via intracompany transfer from a manufacturer; or from the manufacturer's co-licensed partner, third-party logistics provider, or the exclusive distributor to:
(a) a pharmacy or other designated persons authorized under this chapter to dispense or administer prescription drugs to a patient;
(b) a chain pharmacy warehouse that performs intracompany sales or transfers of such drugs to a group of pharmacies under common ownership and control;
(c) a cooperative pharmacy warehouse to a pharmacy that is a member of the pharmacy buying cooperative or GPO to a patient;
(d) an authorized distributor of record, and then to either a pharmacy or other designated persons authorized under this chapter to dispense or administer such drug for use by a patient;
(e) an authorized distributor of record, and then to a chain pharmacy warehouse that performs intracompany sales or transfers of such drugs to a group of pharmacies under common ownership and control; or
(f) an authorized distributor of record to another authorized distributor of record to a licensed pharmaceutical facility or a licensed healthcare practitioner authorized under this chapter to dispense or administer such drug for use by a patient.
(38) "Other health care facilities" means any entity as defined in Utah Code Subsection 26-21-2(13)(a) or Utah Administrative Code R432-1-3(55).
(39) "Parenteral" means a method of drug delivery injected into body tissues but not via the gastrointestinal tract.
(40) "Patient's agent" means a:
(a) relative, friend or other authorized designee of the patient involved in the patient's care; or
(b) if requested by the patient or the individual under Subsection (40)(a), one of the following facilities:
(i) an office of a licensed prescribing practitioner in Utah;
(ii) a long-term care facility where the patient resides; or
(iii) a hospital, office, clinic or other medical facility that provides health care services.
(41) "Pedigree" means a document or electronic file containing information that records each distribution of any given prescription drug.
(42) "PIC", as used in this rule, means the pharmacist-in-charge.
(43) "Prepackaged" or "Prepackaging" means the act of transferring a drug, manually or by use of an automated pharmacy system, from a manufacturer's or distributor's original container to another container in advance of receiving a prescription drug order or for a patient's immediate need for dispensing by a pharmacy or practitioner authorized to dispense in the establishment where the prepackaging occurred.
(44) "Prescription files" means all hard-copy and electronic prescriptions that includes pharmacist notes or technician notes, clarifications or information written or attached that is pertinent to the prescription.
(45) "PTCB" means the Pharmacy Technician Certification Board.
(46) "Qualified continuing education", as used in this rule, means continuing education that meets the standards set forth in Section R156-17b-309.
(47) "Refill" means to fill again.
(48) "Repackage" means repackaging or otherwise changing the container, wrapper, or labeling to further the distribution of a prescription drug, excluding that completed by the pharmacist or DMP responsible for dispensing the product to a patient.
(49) "Research facility" means a facility where research takes place that has policies and procedures describing such research.
(50) "Reverse distributor" means a person or company that retrieves unusable or outdated drugs from a pharmacy for the purpose of removing those drugs from stock and destroying them.
(51) "Sterile products preparation facility" means any facility, or portion of the facility, that compounds sterile products using aseptic technique.
(52) "Supervisor" means a licensed pharmacist or DMP in good standing with the Division.
(53) "Third party logistics provider" means anyone who contracts with a prescription drug manufacturer to provide or coordinate warehousing, distribution, or other similar services on behalf of a manufacturer, but does not take title to the prescription drug or have any authoritative control over the prescription drug's sale. Such third party logistics provider shall be licensed as a pharmaceutical wholesaler under this chapter and be an "authorized distributor of record" to be considered part of the "normal distribution channel".
(54) "Unauthorized personnel" means any person who is not participating in the operational processes of the pharmacy who in some way would interrupt the natural flow of pharmaceutical care.
(55) "Unit dose" means the ordered amount of a drug in a dosage form prepared for a one-time administration to an individual and indicates the name, strength, lot number and beyond use date for the drug.
(56) "Unprofessional conduct", as defined in Title 58, Chapters 1 and 17b, is further defined, in accordance with Subsection 58-1-203(1)(e), in Section R156-17b-502.
(57) "USP-NF" means the United
States Pharmacopeia-National Formulary ([
USP 37-NF 32]), [ 2014] edition, which is official from May 1, [ 2014] through Supplement 2, dated December 1, [ 2014], which is hereby adopted and incorporated by
(58) "Wholesaler" means a wholesale distributor who supplies or distributes drugs or medical devices that are restricted by federal law to sales based on the order of a physician to a person other than the consumer or patient.
(59) "Wholesale distribution" means the distribution of drugs to persons other than consumers or patients, but does not include:
(a) intracompany sales or transfers;
(b) the sale, purchase, distribution, trade, or other transfer of a prescription drug for emergency medical reasons, as defined under 21 CFR 203.3(m), including any amendments thereto;
(c) the sale, purchase, or trade of a drug pursuant to a prescription;
(d) the distribution of drug samples;
(e) the return or transfer of prescription drugs to the original manufacturer, original wholesale distributor, reverse distributor, or a third party returns processor;
(f) the sale, purchase, distribution, trade, or transfer of a prescription drug from one authorized distributor of record to one additional authorized distributor of record during a time period for which there is documentation from the manufacturer that the manufacturer is able to supply a prescription drug and the supplying authorized distributor of record states in writing that the prescription drug being supplied had until that time been exclusively in the normal distribution channel;
(g) the sale, purchase or exchange of blood or blood components for transfusions;
(h) the sale, transfer, merger or consolidation of all or part of the business of a pharmacy;
(i) delivery of a prescription drug by a common carrier; or
(j) other transactions excluded from the definition of "wholesale distribution" under 21 CFR 203.3 (cc), including any amendments thereto.
R156-17b-304. Temporary Licensure.
(1) In accordance with Subsection 58-1-303(1), the Division may issue a temporary pharmacist license to a person who meets all qualifications for licensure as a pharmacist except for the passing of the required examination, if the applicant:
(a) is a graduate of an ACPE accredited
pharmacy school within two months immediately preceding application
for licensure or enrolled in [
the second year of ]a pharmacy graduate residency
(b) submit a complete application for licensure as a pharmacist except the passing of the NAPLEX and MJPE examinations;
(c) submits evidence of having secured employment conditioned upon issuance of the temporary license, and the employment is under the direct, on-site supervision of a pharmacist with an active, non-temporary license that may or may not include a controlled substance license; and
(d) has registered to take the required licensure examinations.
(2) A temporary pharmacist license issued under Subsection (1) expires the earlier of:
(a) six months from the date of issuance;
(b) the date upon which the Division receives notice from the examination agency that the individual has failed either examination twice; or
(c) the date upon which the Division issues the individual full licensure.
(3) An individual who has failed either examination twice shall meet with the Board to request an additional authorization to test. The Division, in collaboration with the Board, may require additional training as a condition for approval of an authorization to retest.
(4) A pharmacist temporary license issued in accordance with this section cannot be renewed or extended.
R156-17b-614e. Class B - Dispensing Drugs from an Emergency
Department and Upon Discharge from a Rural Hospital Pharmacy.
The "Guidelines for Hospital Pharmacies and
Emergency Department Treatment" document, adopted May 21,
2012, by the Division in collaboration with the Utah State Board
of Pharmacy, as posted on the Division website, is the guideline
or standard to be utilized by rural hospital emergency
departments dispensing a short course of necessary medications to
patients when a pharmacy is not open to fill their
] KEY: pharmacists, licensing, pharmacies
Date of Enactment or Last Substantive Amendment: [
Notice of Continuation: January 5, 2015
Authorizing, and Implemented or Interpreted Law: 58-17b-101; 58-17b-601(1); 58-37-1; 58-1-106(1)(a); 58-1-202(1)(a)
More information about a Notice of Proposed Rule is available online.
The Portable Document Format (PDF) version of the Bulletin is the official version. The PDF version of this issue is available at https://rules.utah.gov/publicat/bull-pdf/2015/b20151015.pdf. The HTML edition of the Bulletin is a convenience copy. Any discrepancy between the PDF version and HTML version is resolved in favor of the PDF version.
Text to be deleted is struck through and surrounded by brackets ([
example]). Text to be added is underlined (). Older browsers may not depict some or any of these attributes on the screen or when the document is printed.
For questions regarding the content or application of this rule, please contact Dane Ishihara at the above address, by phone at 801-530-7632, by FAX at 801-530-6511, or by Internet E-mail at firstname.lastname@example.org. For questions about the rulemaking process, please contact the Division of Administrative Rules.